Clinical trial
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell…
NCT00137995 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00137995 |
|---|---|
| Title | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma |
| Official title | Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab |
| Lead sponsor | Lymphoma Study Association, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Large-Cell, Diffuse |
| Intervention type | Drug, Procedure |
| Interventions | Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine and 1 more |
| Enrollment | 481 |
| Start date | Jun 1, 2003 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Aug 30, 2005 |
| Last update posted | Aug 28, 2019 |
| Countries | Australia, Belgium, Czechia, Finland, Germany, Israel, Sweden, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: